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A bs tr ac t
Background
The National Lung Screening Trial was conducted to determine whether three an-
nual screenings (rounds T0, T1, and T2) with low-dose helical computed tomogra-
phy (CT), as compared with chest radiography, could reduce mortality from lung 
cancer. We present detailed findings from the first two incidence screenings 
(rounds T1 and T2).
Methods
We evaluated the rate of adherence of the participants to the screening protocol, the 
results of screening and downstream diagnostic tests, features of the lung-cancer 
cases, and first-line treatments, and we estimated the performance characteristics 
of both screening methods.
Results
At the T1 and T2 rounds, positive screening results were observed in 27.9% and 
16.8% of participants in the low-dose CT group and in 6.2% and 5.0% of partici-
pants in the radiography group, respectively. In the low-dose CT group, the sensitiv-
ity was 94.4%, the specificity was 72.6%, the positive predictive value was 2.4%, and 
the negative predictive value was 99.9% at T1; at T2, the positive predictive value 
increased to 5.2%. In the radiography group, the sensitivity was 59.6%, the specific-
ity was 94.1%, the positive predictive value was 4.4%, and the negative predictive 
value was 99.8% at T1; both the sensitivity and the positive predictive value in-
creased at T2. Among lung cancers of known stage, 87 (47.5%) were stage IA and 
57 (31.1%) were stage III or IV in the low-dose CT group at T1; in the radiography 
group, 31 (23.5%) were stage IA and 78 (59.1%) were stage III or IV at T1. These 
differences in stage distribution between groups persisted at T2.
Conclusions
Low-dose CT was more sensitive in detecting early-stage lung cancers, but its mea-
sured positive predictive value was lower than that of radiography. As compared 
with radiography, the two annual incidence screenings with low-dose CT resulted 
in a decrease in the number of advanced-stage cancers diagnosed and an increase 
in the number of early-stage lung cancers diagnosed. (Funded by the National Can-
cer Institute; NLST ClinicalTrials.gov number, NCT00047385.)
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The National Lung Screening Trial (NLST) was a randomized trial of lung-cancer–specific mortality among partici-
pants in an asymptomatic high-risk cohort who 
underwent screening with the use of low-dose 
helical computed tomography (CT) as compared 
with screening with the use of single-view pos-
teroanterior chest radiography. The NLST showed 
a 20% relative reduction in mortality from lung 
cancer with three rounds of low-dose CT screen-
ing (rounds T0, T1, and T2) as compared with 
radiography.1 In this article, we present more de-
tailed findings from the two incidence screen-
ings (rounds T1 and T2), including information 
on rates of positive screening tests, performance 
characteristics of the screening tests, diagnostic 
follow-up of positive screening results, numbers 
and characteristics of the lung cancers detected, 
and first-line treatments. Detailed findings from 




The design and eligibility criteria of the NLST, as 
well as demographic characteristics of the NLST 
participants, have been described in detail previ-
ously.3,4 Enrollment occurred from August 2002 
through April 2004, and screening occurred 
from August 2002 through September 2007. Par-
ticipants were followed for events that occurred 
through December 31, 2009. A total of 53,454 
participants who were at risk for lung cancer 
were randomly assigned to three annual screen-
ings with either low-dose CT or radiography. The 
study protocol was approved by the institutional 
review board at each of 33 screening centers, and 
written informed consent was obtained from 
each participant before randomization.
Screening
Acquisition factors and measures to control im-
age quality for both low-dose CT and radiographic 
screenings were standardized throughout the 
trial.5 Images were interpreted by individual radi-
ologists on soft-copy display stations without 
computer-assisted image analysis. A positive low-
dose CT screening test was defined as the find-
ing of one or more indeterminate (noncalcified) 
nodules measuring at least 4 mm in the longest 
diameter or, less commonly, mediastinal masses, 
pleural disease, or atelectasis of more than one 
segment. A positive radiographic screening test 
was defined as the finding of a noncalcified nod-
ule of any size or another abnormality potential-
ly related to lung cancer. At the discretion of the 
radiologist, nodules at incidence screenings that 
showed no change in growth or consistency from 
those detected at the previous screening could be 
classified as “positive, stable”; nodules that were 
stable across all three annual screenings could 
be classified as “positive, stable” or “negative.”
Outcomes and Follow-up
The primary end point of the NLST was lung-
cancer–specific mortality. Data on participants 
were obtained by means of medical-record ab-
straction and included the types and results of 
downstream diagnostic tests; histologic features, 
grade, and stage of lung cancers diagnosed; his-
tologic features of other cancers; details of first-
line treatments for lung cancer; and deaths from 
all causes. The methods for the histopathological 
classification of lung cancer, lung-cancer staging, 
and determination of vital status and cause of 
death have been described previously.1,6-9
Statistical Analysis
We compared the two screening groups with re-
spect to adherence of the participants to the test-
ing protocol, screening results, types of diagnos-
tic procedures and results, and initial treatment 
information. Measures of diagnostic and predic-
tive accuracy at the T1 and T2 rounds were de-
rived with the use of data only from participants 
who had adequate screening examinations in the 
respective rounds and for whom lung-cancer sta-
tus was known. For each dichotomous (positive 
vs. negative) screening result, lung cancer was 
classified as present or absent at the time of the 
screening on the basis of specific rules related to 
the timing of lung-cancer diagnosis relative to 
screening intervals and diagnostic testing (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). The sensitivity, 
specificity, positive predictive value, and negative 
predictive value were calculated according to ac-
cepted definitions, and confidence intervals were 
calculated with the use of bootstrapping.10 Screen-
ings of participants with unknown lung-cancer 
status were excluded from calculations of screen-
ing test performance. We calculated the confi-
dence intervals for incidence ratios assuming a 
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Poisson distribution for the number of events 
and a normal distribution of the logarithm of the 
ratio, using asymptotic methods. All tabulations 
were performed with the use of SAS/STAT soft-
ware, version 9.1 of the SAS System for Unix or 
version 9.2 for PC (SAS Institute).
R esult s
Screening
At the T1 screening, 94.0% of eligible participants 
in the low-dose CT group (24,715 of 26,285) and 
91.2% of eligible participants in the radiography 
group (24,089 of 26,410) underwent screening 
(Table 1). T1 screening results were positive in 
27.9% of the participants who were screened 
in the low-dose CT group (6901 of 24,715) and 
in 6.2% of the participants who were screened in 
the radiography group (1482 of 24,089). A total of 
186 participants received a diagnosis of lung can-
cer in the low-dose CT group at T1: 168 of 6901 
participants with positive screening results, 10 
of 17,814 participants with negative screening 
results, 6 of 1570 participants who were not 
screened at T1, and 2 of 437 ineligible participants 
with lung cancers that were first diagnosed dur-
ing the T1 screening year (Fig. 1A). In the radiog-
raphy group, 133 participants received a diagnosis 
of lung cancer at T1: 65 of 1482 participants with 
positive screening results, 44 of 22,607 partici-
pants with negative screening results, 21 of 2321 
participants who were not screened, and 3 of 322 
ineligible participants with lung cancers that 
were diagnosed during the T1 screening year. 
The sensitivity of low-dose CT was 94.4% (95% 
confidence interval [CI], 90.8 to 97.6), the speci-
ficity was 72.6% (95% CI, 72.0 to 73.1), the posi-
tive predictive value was 2.4% (95% CI, 2.1 to 
2.8), and the negative predictive value was 99.9% 
(95% CI, 99.9 to 100.0) (Table S1 in the Supple-
mentary Appendix). The sensitivity of radiogra-
phy was 59.6% (95% CI, 50.0 to 69.0), the speci-
ficity was 94.1% (95% CI, 93.8 to 94.4), the 
positive predictive value was 4.4% (95% CI, 3.3 to 
5.5), and the negative predictive value was 99.8% 
(95% CI, 99.7 to 99.9).
At the T2 screening, 92.9% of eligible partici-
pants in the low-dose CT group (24,102 of 
25,942) and 89.4% of eligible participants in the 
radiography group (23,346 of 26,110) underwent 
screening (Fig. 1B and Table 1). T2 screening 
results were positive in 16.8% of persons who 
were screened in the low-dose CT group (4054 of 
24,102) and in 5.0% of the persons who were 
screened in the radiography group (1174 of 
23,346). A total of 237 participants received a 
diagnosis of lung cancer at T2 in the low-dose 
CT group: 211 of 4054 participants with positive 
screening results, 16 of 20,048 participants with 
negative screening results, 7 of 1840 participants 
who were not screened at T2, and 3 of 780 in-
eligible participants with lung cancers that were 
diagnosed during the T2 screening year (Fig. 
1B). In the radiography group, 144 participants 
received a diagnosis of lung cancer at T2: 78 of 
1174 participants with positive screening results, 
44 of 22,172 participants with negative screen-
ing results, 18 of 2764 participants who were not 
screened, and 4 of 622 participants who were 
ineligible for the T2 screening but received a 
diagnosis of lung cancer during the T2 screen-
ing year (Fig. 1B). The sensitivity of low-dose CT 
was 93.0% (95% CI, 89.7 to 96.3), the specificity 
was 83.9% (95% CI, 83.4 to 84.3), the positive 
predictive value was 5.2% (95% CI, 4.6 to 5.9), 
and the negative predictive value was 99.9% 
Table 1. Screening Eligibility, Compliance, and Rates of Positive Screening Tests According to Screening Round 
and Study Group.
Screening


















T1 26,285 24,715 (94.0) 6901 (27.9) 26,410 24,089 (91.2) 1482 (6.2)
T2 25,942 24,102 (92.9) 4054 (16.8) 26,110 23,346 (89.4) 1174 (5.0)
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(95% CI, 99.9 to 100.0) (Table S1 in the Supple-
mentary Appendix). The sensitivity of radiogra-
phy was 63.9% (95% CI, 55.2 to 72.1), the speci-
ficity was 95.3% (95% CI, 95.0 to 95.6), the 
positive predictive value was 6.7% (95% CI, 5.2 to 
8.2), and the negative predictive value was 99.8% 
(95% CI, 99.7 to 99.9).
The rates of positive screening tests in both 
groups decreased at the T2 screening, primarily 
because abnormalities that were stable across all 
three rounds could be categorized as negative 
screening results (Table 1). Data on lung-cancer 
status according to the participants’ age, sex, 
and race or ethnic group are provided in Tables 
S2a and S2b in the Supplementary Appendix. In 
both the low-dose CT and radiography groups, 
43% of participants who underwent incidence 
screening were 55 to 59 years of age at study 
entry, but the rates of lung cancer among par-
ticipants in this age group were the lowest (in the 
low-dose CT group, 0.4% at the T1 screening and 
0.7% at the T2 screening, and in the radiography 
group, 0.3% at both the T1 and T2 screenings).
Follow-up of Positive Results
Information on diagnostic follow-up of positive 
screening results was available for the majority of 
participants in both groups at both screening 
rounds (Tables S3a and S3b in the Supplementary 
Appendix). Beyond office visits and physical 
 examinations, imaging examinations, including 
diagnostic chest CT and 18F-fluorodeoxyglucose–
positron-emission tomography (FDG-PET), were 
the most commonly performed procedures for 
follow-up of positive tests in both groups and at 
both screening rounds. FDG-PET was performed 
much more frequently in participants with a lung-
cancer diagnosis than in those with no lung cancer. 
In the low-dose CT group, both surgical and bron-
choscopic interventional procedures were per-
formed more commonly than percutaneous biop-
sies in both participants with and those without 
lung-cancer diagnoses; the frequencies of these 
interventional procedures were more evenly dis-
tributed in the radiography group. Among partici-
pants in the low-dose CT group who underwent 
thoracotomy because of positive screening results, 
the proportion in whom lung cancer was not diag-
nosed was 18.9% at the T1 screening and 15.9% 
at the T2 screening. The respective proportions in 
the radiography group were 11.4% and 13.6%.
Relationship of Nodule Size to Lung Cancer
At the T1 screening, 161 of 168 CT-detected lung 
cancers (95.8%) and 60 of 65 radiography-detected 
lung cancers (92.3%) were diagnosed on the ba-
sis of an observed lung nodule or mass (Table 2). 
Among patients with lung cancers that were di-
agnosed with the use of low-dose CT screening at 
T1, 58 (34.5%) had nodules that were 4 to 10 mm 
in diameter, 74 (44.0%) had nodules that were 11 
to 20 mm, 20 (11.9%) had nodules that were 21 
to 30 mm, and 8 (4.8%) had masses larger than 
30 mm. The positive predictive value for the de-
tection of a nodule of any size with the use of 
low-dose CT at T1 was 2.4%, but it increased to 
58.2% for positive screening results with subse-
quent biopsy. For nodules that were 4 to 6 mm 
diameter, the positive predictive value at T1 was 
0.3%. In the radiography group, the largest nodule 
or mass observed among 65 lung cancers detected 
at the T1 screening was 4 to 10 mm in diameter 
in 9 participants (13.8%), 11 to 20 mm in 22 par-
ticipants (33.8%), 21 to 30 mm in 16 participants 
(24.6%), and more than 30 mm in 10 partici-
pants (15.4%). The positive predictive value for 
the detection of a nodule of any size at the T1 
screening in the radiography group was 4.4%, 
but it increased to 67.4% for positive screening 
results with subsequent biopsy. In both groups, 
the positive predictive value for detection of a 
nodule increased as the nodule size increased 
from 4 to 30 mm. In the radiography group, the 
positive predictive value for nodules smaller than 
4 mm was relatively high; it is unclear whether 
these nodules corresponded to a lung cancer or 
prompted follow-up assessments that led to an 
ultimate diagnosis of lung cancer, although the 
latter explanation is more likely. In both groups, 
detection of masses larger than 30 mm had a 
slightly decreased positive predictive value relative 
to the detection of nodules that were 21 to 30 mm, 
probably because pneumonia was interpreted as 
a positive screening result.
In both groups, the proportions of cancers 
associated with a lung nodule or mass at the T2 
screening were similar to those seen at the T1 
screening (Table 3). At T2, the positive predictive 
value for detection of a nodule was 5.2% on low-
dose CT and 6.4% on radiographic screening; 
the corresponding positive predictive values for 
detection of nodules that were 4 to 6 mm in di-
ameter were 0.7% and 2.5%. With low-dose CT, 
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the positive predictive value increased with in-
creasing nodule size at T2; this was not the case 
with radiography because of a decrease in the 
positive predictive value for masses larger than 
30 mm and two cases in which nodules smaller 
than 4 mm were associated with lung cancer. As 
expected, in both groups, detection of stable 
nodules at T2 was less predictive of lung cancer 
than detection of new nodules. For positive 
screening tests with subsequent biopsy, the posi-
tive predictive value increased to 65.8% with low-
dose CT and to 67.9% with radiography. At both 
the T1 and T2 screenings, there was no clear 
relationship between nodule size and stage of 
non–small-cell lung cancer in either group (Table 
S4 in the Supplementary Appendix).
53,454 Participants underwent randomization
26,722 Were assigned to low-dose
CT screening
26,732 Were assigned to chest
radiographic screening
322 Were not eligible
144 Died
178 Received diagnosis of
lung cancer before
screening
437 Were not eligible
161 Died
276 Received diagnosis of
lung cancer before
screening
26,285 Were eligible 26,410 Were eligible





17,788 Did not have
          lung cancer
   10 Had lung cancer
16 Had unknown 
           lung-cancer status





2321 Were not screened
2015 Declined to participate
238 Withdrew from study
18 Underwent incorrect
screening
7 Had inadequate screening
43 Had other reasons
1570 Were not screened
1383 Declined to participate
153 Withdrew from study
9 Underwent incorrect
screening
2 Had inadequate screening
23 Had other reasons
  6728 Did not have
  lung cancer
 168 Had lung cancer
     5 Had unknown 
        lung-cancer status 
  1416 Did not have
  lung cancer
65 Had lung cancer
    1 Had unknown 
       lung-cancer status
22,521 Did not have
            lung cancer
44 Had lung cancer 
42 Had unknown 
     lung-cancer status
A T1 Screening
Figure 1. Randomization and Follow-up of the Study Participants.
Panel A shows randomization and follow-up for the T1 screening. During the T1 study year, 2 of 437 ineligible participants in the low-dose 
computed tomography (CT) group and 3 of 322 ineligible participants in the radiography group received a diagnosis of lung cancer (data 
not shown). Panel B shows randomization and follow-up for the T2 screening. During the T2 study year, 3 of 780 ineligible participants in 
the low-dose CT group and 4 of 622 ineligible participants in the radiography group received a diagnosis of lung cancer (data not shown). 
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Stage Distribution and Treatment of Lung 
Cancer
At the T1 screening, the clinical or pathological 
stage was known in 183 of 186 participants in 
the low-dose CT group (Table 4). Among partici-
pants with lung cancer of a known stage, 87 had 
stage IA cancer (47.5%); 39 had stage IB, IIA, or 
IIB cancer (21.3%); and 57 had stage III or IV 
cancer (31.1%). Among participants in the radi-
ography group who received a lung-cancer diag-
nosis at T1, the stage was known in 132 of 133 
participants; 31 had stage IA cancer (23.5%); 23 had 
stage IB, IIA, or IIB cancer (17.4%); and 78 had 
stage III or IV cancer (59.1%). Stage distributions 
at T2 were similar to those at T1 in each group.
In the low-dose CT group, the increase in 
early-stage lung cancers was associated with a 
decrease in late-stage lung cancers. Over the 
course of the trial, the incidence of stage IV lung 
cancer was 138 cases per 100,000 person-years 
in the low-dose CT group, as compared with 204 
cases per 100,000 person-years in the radiogra-
phy group (rate ratio, 0.68; 95% CI, 0.57 to 0.80).
The distribution of stage according to screen-
ing result was fairly consistent between the T1 
and T2 screenings in the low-dose CT group. At 
53,454 Participants underwent randomization
26,722 Were assigned to low-dose
CT screening
26,732 Were assigned to chest
radiographic screening
622 Were not eligible
342 Died
280 Received diagnosis of
lung cancer before
screening
780 Were not eligible
341 Died
439 Received diagnosis of
lung cancer before
screening
25,942 Were eligible 26,110 Were eligible





19,968 Did not have
          lung cancer
   16 Had lung cancer
 64 Had unknown 
            lung-cancer status





2764 Were not screened
2372 Declined to participate
325 Withdrew from study
14 Underwent incorrect
screening
6 Had inadequate screening
47 Had other reasons
1840 Were not screened
1577 Declined to participate
224 Withdrew from study
12 Underwent incorrect
screening
1 Had inadequate screening
26 Had other reasons
3838 Did not have
       lung cancer
        211 Had lung cancer
         5 Had unknown 
                  lung-cancer status
1094 Did not have
       lung cancer
      78 Had lung cancer
     2 Had unknown 
              lung-cancer status
22,067 Did not have
          lung cancer
     44 Had lung cancer
  61 Had unknown 
             lung-cancer status
B T2 Screening
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both T1 and T2, the majority of stage IA lung 
cancers were detected in participants with screen-
ing results that were positive on low-dose CT; 
lung cancers diagnosed in participants with 
negative results (interval cancers) were predomi-
nantly advanced-stage cancers. In the radiogra-
phy group, as compared with the low-dose CT 
group, lung cancers detected in participants with 
positive results were more equally distributed 
among early, intermediate, and advanced stages. 
Of small-cell lung cancers detected by means of 
low-dose CT, 92.3% of those detected at T1 and 
66.7% of those detected at T2 were late-stage 
cancers; corresponding percentages in the radi-
ography group were 42.9% and 66.7% (data not 
shown). For lung cancers at each stage, partici-
pants in the low-dose CT and radiography 
groups received similar treatment (Tables S5a 
and S5b in the Supplementary Appendix).
Histologic Characteristics of Diagnosed 
Lung Cancers
The most common histologic types of lung can-
cer in both screening groups and at both screen-
ings were adenocarcinoma (at T1, 36.6% of can-
cers diagnosed in the low-dose CT group and 
32.8% of those diagnosed in the radiography 
group; at T2, 34.9% in the low-dose CT group 
and 33.1% in the radiography group) and squa-
mous-cell carcinoma (at T1, 21.0% of cancers 
diagnosed in the low-dose CT group and 22.9% 
of those diagnosed in the radiography group; at 
T2, 26.0% in the low-dose CT group and 23.9% 
in the radiography group) (Table S6 in the Sup-
plementary Appendix).
In the low-dose CT group, lung cancers char-
acterized as bronchioloalveolar-cell carcinoma 
were predominantly diagnosed after a positive 
screening and accounted for 17.3% and 13.3% of 
Table 4. Stage of Lung Cancers, According to Screening Round, Study Group, and Screening Result.* 
Screening Round 
and Stage Low-Dose CT Chest Radiography
Positive Negative
No 





Stage IA 86/165 (52.1) 1/10 (10.0) 0 87/183 (47.5) 23/65 (35.4) 6/43 (14.0) 2/24 (8.3) 31/132 (23.5)
Stage IB 18/165 (10.9) 1/10 (10.0) 2/8 (25.0) 21/183 (11.5) 9/65 (13.8) 1/43 (2.3) 1/24 (4.2) 11/132 (8.3)
Stage IIA 11/165 (6.7) 0 0 11/183 (6.0) 4/65 (6.2) 2/43 (4.7) 1/24 (4.2) 7/132 (5.3)
Stage IIB 6/165 (3.6) 0 1/8 (12.5) 7/183 (3.8) 3/65 (4.6) 1/43 (2.3) 1/24 (4.2) 5/132 (3.8)
Stage IIIA 13/165 (7.9) 1/10 (10.0) 0 14/183 (7.7) 6/65 (9.2) 6/43 (14.0) 2/24 (8.3) 14/132 (10.6)
Stage IIIB 13/165 (7.9) 4/10 (40.0) 2/8 (25.0) 19/183 (10.4) 2/65 (3.1) 6/43 (14.0) 4/24 (16.7) 12/132 (9.2)
Stage IV 18/165 (10.9) 3/10 (30.0) 3/8 (37.5) 24/183 (13.1) 18/65 (27.7) 21/43 (48.8) 13/24 (54.2) 52/132 (39.4)
Unknown† 3/168 (1.8) 0 0 3/186 (1.6) 0 1/44 (2.3) 0 1/133 (0.8)
T2 screening round
Stage IA 113/204 (55.4) 2/16 (12.5) 1/10 (10.0) 116/230 (50.4) 27/77 (35.1) 4/44 (9.1) 4/22 (18.2) 35/143 (24.5)
Stage IB 28/204 (13.7) 0 3/10 (30.0) 31/230 (13.5) 10/77 (13.0) 3/44 (6.8) 0 13/143 (9.1)
Stage IIA 8/204 (3.9) 0 0 8/230 (3.5) 7/77 (9.1) 0 2/22 (9.1) 9/143 (6.3)
Stage IIB 3/204 (1.5) 2/16 (12.5) 0 5/230 (2.2) 0 3/44 (6.8) 0 3/143 (2.1)
Stage IIIA 15/204 (7.4) 0 0 15/230 (6.5) 10/77 (13.0) 7/44 (15.9) 1/22 (4.5) 18/143 (12.6)
Stage IIIB 15/204 (7.4) 4/16 (25.0) 1/10 (10.0) 20/230 (8.7) 10/77 (13.0) 6/44 (13.6) 5/22 (22.7) 21/143 (14.7)
Stage IV 22/204 (10.8) 8/16 (50.0) 5/10 (50.0) 35/230 (15.2) 13/77 (16.9) 21/44 (47.7) 10/22 (45.5) 44/143 (30.8)
Unknown‡ 7/211 (3.3) 0 0 7/237 (3.0) 1/78 (1.3) 0 0 1/144 (0.7)
* Cancer-stage classification was based on the sixth edition of the Cancer Staging Manual of the American Joint Committee on Cancer.7 The 
denominators for cancer stage were the total number of lung cancers of known stage in each screening-result category.
† The lung cancers of unknown stage at the T1 screening round included 4 cancers with stage information that could not be classified.
‡ The lung cancers of unknown stage at the T2 screening round included 2 carcinoids, 1 occult carcinoma, 1 with no evidence of malignancy, 
and 4 with stage information that could not be classified.
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all lung cancers detected on positive screening at 
T1 and T2, respectively. Bronchioloalveolar-cell 
carcinoma included pure adenocarcinoma in situ, 
minimally invasive adenocarcinoma, and inva-
sive adenocarcinoma, lepidic predominant (i.e., 
neoplastic cell growth restricted to preexisting 
alveolar structures); these histologic subtypes 
are now classified separately.11 Few bronchioloal-
veolar-cell carcinomas were diagnosed in the 
radiography group, probably because they are 
difficult to discern on planar imaging. The fre-
quency of small-cell carcinoma was similar in 
the low-dose CT and radiography groups at both 
screenings, but in the low-dose CT group, small-
cell carcinoma was more commonly detected in 
participants with positive results than in those 
with negative results, whereas in the radiogra-
phy group, it was more commonly diagnosed in 
participants with negative screening tests than 
in those with positive results.
Discussion
At the T1 and T2 incidence screenings in the 
NLST, the percentage of positive screening re-
sults in the low-dose CT group was more than 
three times as high as that in the radiography 
group. With low-dose CT, the number of lung 
cancers that were detected by screening was in-
creased by a factor of 2.7, and the number of in-
terval lung cancers (diagnosed after a negative 
screening) was decreased by 70%. The reduction 
in lung-cancer mortality observed with low-dose 
CT screening was coupled with a shift to detec-
tion of earlier-stage non–small-cell lung cancers 
at incidence screenings.
In the low-dose CT group, 27.9% of all results 
at the T1 screening and 16.8% of all results at 
the T2 screening were positive; 2.4% and 5.2% 
of positive screening tests were associated with 
a lung-cancer diagnosis, respectively. The higher 
positive predictive value at T2 is partly due to the 
fact that a nodule observed to be stable over 
three consecutive screenings could be interpret-
ed as “negative” at the last screening.
Although this analysis does not address the 
unique features of nodules that distinguish lung 
cancers from noncancers, some preliminary ob-
servations can be made. With low-dose CT, the 
positive predictive value increased as nodule size 
increased up to 30 mm; this pattern was less 
pronounced with radiography. For lesions larger 
than 30 mm, the positive predictive value did not 
reliably increase in either group, possibly be-
cause of misinterpretation of pneumonia as a 
positive screening result. Moreover, nodules in 
some size categories in the radiography group 
were few in number, resulting in large uncer-
tainties (confidence intervals) in the estimates of 
positive predictive value.
In both groups, more lung cancers were diag-
nosed at T2 than at T1. It is likely that many 
positive screening results at T0 were ultimately 
diagnosed as lung cancer at T2, after observa-
tion of growth over time. Also, because T2 was 
the final screening round in the trial, abnormali-
ties detected in that round may have been fol-
lowed more aggressively than those detected at 
earlier rounds.
The performance characteristics of low-dose 
CT are influenced by the risk (pretest probability) 
of lung cancer among persons who undergo 
screening. Given the low proportion of lung 
cancers in participants 55 to 59 years of age who 
underwent screening, increasing the minimum 
age for screening may have merit; however, 
other risk factors, in addition to age, need to be 
considered in order to obtain the greatest pos-
sible benefit of screening.12 As our knowledge 
evolves, screening guidelines will be informed 
by integrating multiple demographic and clini-
cal risk factors, measures of field injury such as 
airflow obstruction, and validated biomarkers of 
lung-cancer predisposition, measured in blood 
or other readily accessible specimens.13-15
The performance of low-dose CT is also 
 influenced by the definition of positive screen-
ing results, which will be refined in light of 
the experience of the NLST as well as other 
randomized trials and single-group studies. In 
the NLST, screening interpretations were di-
chot omous. Other ongoing randomized trials, 
including the Danish Lung Cancer Screening 
Trial  (ClinicalTrials.gov number, NCT00496977) 
and the Dutch–Belgian Randomised Controlled 
Trial for Lung Cancer Screening in High-Risk 
Subjects (NELSON; Current Controlled Trials 
number, ISRCTN63545820), have added an “in-
de terminate” interpretation category for nodules 
between the lower (negative) and upper (positive) 
size thresholds, with CT repeated at 3 months 
to classify the findings as negative or positive.16,17 
This two-step approach has little effect on overall 
medical resource utilization, since patients with 
nodules within this indeterminate size range typ-
ically undergo early repeat low-dose CT; however, 
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the change in classification significantly im-
proves the positive predictive value of low-dose 
CT screening relative to that observed in the 
NLST. More important, the designation of “inde-
terminate” provides a more realistic representa-
tion of the risk of lung cancer for both patient 
and provider, given that the majority of such 
nodules are ultimately benign.
Increasing the minimum size threshold for 
positive screening tests can also reduce the fre-
quency of the diagnostic workup.18 In the NLST, 
nodules that were 4 to 6 mm in diameter ac-
counted for roughly half the positive screening 
results with low-dose CT at both time points, 
but such nodules were associated with lung can-
cer in less than 1% of participants. Future ef-
forts to develop diagnostic prediction models in 
this rapidly moving field should be informed by 
aggregating data on nodule size from all screen-
ing trials; these efforts should balance the ef-
fects of test performance at a given nodule size 
with potential delays in diagnosis and effects on 
a reduction in mortality. The size threshold of a 
nodule that indicates a positive screening, wheth-
er based on diameter or computer-assisted volu-
metric analysis,19,20 will vary depending on the 
level of risk of lung cancer and must be assessed 
in the context of the specific cohort undergoing 
screening.
The NLST had a number of limitations. First, 
the results may have been influenced by the 
healthy-volunteer effect, although this effect 
would be similar in the two screening groups.1 
Second, in this analysis, data on medical resource 
utilization was restricted to participants with 
positive screening results. Our data underesti-
mate the numbers of additional procedures and 
attendant risks that could result from reported 
findings other than those related to potential 
lung cancer. Data on these findings have been 
collected in a subgroup of NLST participants 
but are not reported here. Finally, the NLST 
included three annual screenings.1 The results 
of ongoing randomized trials in Europe and 
mathematical modeling will help to inform the 
effects of additional years of screening or dif-
ferent screening intervals on stage shift and 
mortality reduction.
The two incidence screenings in the NLST 
provide evidence that in a high-risk cohort, an-
nual screening with low-dose CT detects more 
lung cancers than radiography and results in a 
stage shift toward early-stage, non–small-cell 
lung cancers, which are potentially curable. The 
performance characteristics of low-dose CT may 
be enhanced by determining the most appropri-
ate risk cohort, refining both algorithms for 
interpreting the results of screening and defini-
tions of positive findings, and determining the 
appropriate duration and timing of screening.
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